West Pharmaceutical Services, Inc. (NYSE:WST) to Issue Quarterly Dividend of $0.22

West Pharmaceutical Services, Inc. (NYSE:WST) announced a quarterly dividend on Tuesday, July 21st. Shareholders of record on Wednesday, July 29th will be given a dividend of 0.22 per share by the medical instruments supplier on Wednesday, August 5th. This represents a c) dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Wednesday, July 29th.

West Pharmaceutical Services has increased its dividend payment by an average of 0.1%annually over the last three years. West Pharmaceutical Services has a payout ratio of 12.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect West Pharmaceutical Services to earn $9.52 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 9.2%.

West Pharmaceutical Services Stock Up 2.0%

WST stock opened at $359.32 on Wednesday. The stock’s 50 day simple moving average is $334.27 and its 200 day simple moving average is $286.00. West Pharmaceutical Services has a fifty-two week low of $211.10 and a fifty-two week high of $367.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The company has a market cap of $25.39 billion, a P/E ratio of 48.04, a price-to-earnings-growth ratio of 2.85 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts expect that West Pharmaceutical Services will post 8.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently made changes to their positions in the business. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services during the 4th quarter valued at approximately $25,000. CYBER HORNET ETFs LLC bought a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $25,000. Cornerstone Planning Group LLC boosted its holdings in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares in the last quarter. Bayban bought a new stake in West Pharmaceutical Services during the fourth quarter worth about $27,000. Finally, Private Trust Co. NA boosted its position in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.